136 related articles for article (PubMed ID: 25065867)
1. [Myeloma bone disease].
Abe M
Clin Calcium; 2014 Aug; 24(8):1159-68. PubMed ID: 25065867
[TBL] [Abstract][Full Text] [Related]
2. [Mechanisms of myeloma-induced bone disease].
Abe M
Clin Calcium; 2016 May; 26(5):699-706. PubMed ID: 27117615
[TBL] [Abstract][Full Text] [Related]
3. [Cytokines and myeloma bone disease].
Abe M
Clin Calcium; 2014 Jun; 24(6):871-8. PubMed ID: 24870838
[TBL] [Abstract][Full Text] [Related]
4. [Cytokines in bone diseases. Cytokines and myeloma bone disease].
Abe M
Clin Calcium; 2010 Oct; 20(10):1474-80. PubMed ID: 20890028
[TBL] [Abstract][Full Text] [Related]
5. [Myeloma bone disease and RANKL signaling].
Abe M
Clin Calcium; 2011 Aug; 21(8):1167-74. PubMed ID: 21814021
[TBL] [Abstract][Full Text] [Related]
6. [Link between osteoclastogenesis, angiogenesis and myeloma expansion].
Abe M
Clin Calcium; 2008 Apr; 18(4):473-9. PubMed ID: 18379029
[TBL] [Abstract][Full Text] [Related]
7. New potential targets for treating myeloma bone disease.
Roodman GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
[TBL] [Abstract][Full Text] [Related]
8. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
9. LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease.
Brunetti G; Rizzi R; Oranger A; Gigante I; Mori G; Taurino G; Mongelli T; Colaianni G; Di Benedetto A; Tamma R; Ingravallo G; Napoli A; Faienza MF; Mestice A; Curci P; Specchia G; Colucci S; Grano M
Oncotarget; 2014 Dec; 5(24):12950-67. PubMed ID: 25460501
[TBL] [Abstract][Full Text] [Related]
10. [Development of the therapies targeting the interaction of myeloma cells with its bone marrow microenvironment].
Abe M
Rinsho Ketsueki; 2013 Jun; 54(6):522-32. PubMed ID: 23823090
[No Abstract] [Full Text] [Related]
11. [Bone disease in multiple myeloma and its mechanism].
Abe M
Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
[TBL] [Abstract][Full Text] [Related]
12. [Mutual interaction between myeloma cells and bone marrow microenvironment].
Abe M
Rinsho Ketsueki; 2009 Jun; 50(6):453-60. PubMed ID: 19571504
[No Abstract] [Full Text] [Related]
13. [Wnt signaling in myeloma.].
Abe M
Clin Calcium; 2019; 29(3):349-355. PubMed ID: 30814381
[TBL] [Abstract][Full Text] [Related]
14. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
15. The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3.
Brunetti G; Oranger A; Mori G; Centonze M; Colaianni G; Rizzi R; Liso V; Zallone A; Grano M; Colucci S
Ann N Y Acad Sci; 2010 Mar; 1192():298-302. PubMed ID: 20392250
[TBL] [Abstract][Full Text] [Related]
16. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.
Abe M
Int J Hematol; 2011 Oct; 94(4):334-343. PubMed ID: 22005835
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of myeloma bone disease.
Roodman GD
Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2.
Yen CH; Hsu CM; Hsiao SY; Hsiao HH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937821
[TBL] [Abstract][Full Text] [Related]
20. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
